Healthconn Corp. (TPEX:6665)
19.65
+0.35 (1.81%)
Jul 15, 2026, 12:54 PM CST
Healthconn Revenue
In the year 2025, Healthconn had annual revenue of 1.13B TWD, down -9.76%. Healthconn had revenue of 583.06M in the half year ending December 31, 2025, a decrease of -8.20%.
Revenue
1.13B
Revenue Growth
-9.76%
P/S Ratio
0.77
Revenue / Employee
5.52M
Employees
205
Market Cap
875.26M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.13B | -122.32M | -9.76% |
| Dec 31, 2024 | 1.25B | -2.51M | -0.20% |
| Dec 31, 2023 | 1.26B | -289.50M | -18.73% |
| Dec 31, 2022 | 1.55B | 182.35M | 13.38% |
| Dec 31, 2021 | 1.36B | -144.18M | -9.57% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| PharmaEssentia | 17.50B |
| Anxo Pharmaceutical | 843.26M |
| Perfect Medical Industry | 779.02M |
| Kim Forest Enterprise | 570.49M |
| Meribank Biotech | 471.76M |
| TCI GENE | 273.61M |
| GeneReach Biotechnology | 232.55M |
| Caliway Biopharmaceuticals | 38.04M |